Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple system atrophy: pathophysiology and management.

G K Wenning1, S Braune

  • 1Department of Neurology, University Hospital, Innsbruck, Austria. gregor.wenning@uibk.ac.at

CNS Drugs
|November 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

42th Conference of the German Society for Clinical Microcirculation and Hemorheology (DGKMH).

Clinical hemorheology and microcirculation·2024
Same author

[Curriculum "Tracheostomy management in dysphagia therapy"].

HNO·2024
Same author

[Curriculum "Tracheostomy management in dysphagia therapy"].

Der Nervenarzt·2024
Same author

Response of Arthrospira platensis to different temperatures regarding growth and biochemical composition.

Clinical hemorheology and microcirculation·2023
Same author

Effects of Arthrospira platensis-derived phycocyanin on blood cells1.

Clinical hemorheology and microcirculation·2022
Same author

Effect of Arthrospira powders from different producers on the formation of endothelial cell monolayers.

Clinical hemorheology and microcirculation·2021
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Multiple system atrophy (MSA) is a neurodegenerative disease affecting individuals in their early fifties. Early identification of autonomic dysfunction is key, as motor symptom treatments offer limited benefit.

Area of Science:

  • Neuroscience
  • Neurology

Background:

  • Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder typically emerging in individuals' early fifties.
  • It is characterized by relentless progression and a mean survival of approximately 9 years.
  • Clinical presentation includes autonomic/urogenital failure, with subtypes MSA-P (parkinsonism, 80%) and MSA-C (cerebellar ataxia, 20%).

Purpose of the Study:

  • To summarize the clinical and pathological features of Multiple System Atrophy (MSA).
  • To highlight the importance of early diagnosis of autonomic and urogenital symptoms.
  • To discuss current and future therapeutic strategies for MSA.

Main Methods:

  • Review of clinical and pathological characteristics of MSA.
  • Analysis of treatment outcomes for autonomic and motor features.

Related Experiment Videos

  • Discussion of potential future therapies including neurotransplantation and neuroprotection.

    • Main Results:

    • Autonomic/urogenital failure is a dominant clinical feature of MSA.
    • Motor features are often poorly responsive to pharmacological treatment, with transient levodopa benefit in some MSA-P patients.
    • Early identification of autonomic symptoms allows for effective management.

    Conclusions:

    • Early detection and management of autonomic/urogenital dysfunction in MSA are crucial for patient care.
    • Current pharmacological treatments for motor symptoms in MSA are largely ineffective.
    • Future research into neurotransplantation and neuroprotection strategies holds promise for slowing disease progression and improving treatment response in MSA.